These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32129681)

  • 21. Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis.
    Pogosova N; Bosch J; Bhatt DL; Fox KAA; Connolly SJ; Alings M; Verhamme P; Muehlhofer E; Shestakovska O; Yusuf S; Eikelboom JW
    Circulation; 2022 Jun; 145(25):1875-1877. PubMed ID: 35728054
    [No Abstract]   [Full Text] [Related]  

  • 22. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
    Kruger PC; Eikelboom JW; Yusuf S
    Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
    [No Abstract]   [Full Text] [Related]  

  • 23. Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review.
    Parascandolo E; Eisen A
    Expert Rev Cardiovasc Ther; 2020 Sep; 18(9):577-585. PubMed ID: 32755422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
    Ringwala SM; Dibattiste PM; Schneider DJ
    J Thromb Thrombolysis; 2012 Oct; 34(3):291-6. PubMed ID: 22528328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
    Branch KRH; Probstfield JL; Bosch J; Bhatt DL; Maggioni AP; Muehlhofer E; Avezum A; Widimsky P; Connolly SJ; Yi Q; Shestakovska O; Yusuf S; Eikelboom JW
    Am Heart J; 2023 Apr; 258():60-68. PubMed ID: 36646196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
    Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
    Fox KAA; Anand SS; Aboyans V; Cowie MR; Debus ES; Zeymer U; Monje D; Vogtländer K; Lawatscheck R; Gay A
    Am Heart J; 2020 Apr; 222():166-173. PubMed ID: 32092505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rivaroxaban with aspirin for the secondary prevention of cardiovascular events in Chinese patients with stable cardiovascular diseases: subgroup analysis of COMPASS].
    Liang Y; Gong ZB; Lou KJ; Liu LS; Zhu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Sep; 49(9):873-879. PubMed ID: 34530594
    [No Abstract]   [Full Text] [Related]  

  • 29. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
    Cowie MR; Lamy A; Levy P; Mealing S; Millier A; Mernagh P; Cristeau O; Bowrin K; Briere JB
    Cardiovasc Res; 2020 Sep; 116(11):1918-1924. PubMed ID: 31807773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
    McClure GR; Kaplovitch E; Narula S; Bhagirath VC; Anand SS
    Curr Cardiol Rep; 2019 Aug; 21(10):115. PubMed ID: 31471666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
    Weisshaar S; Litschauer B; Gouya G; Mayer P; Smerda L; Kapiotis S; Kyrle PA; Eichinger S; Wolzt M
    J Thromb Haemost; 2014 Nov; 12(11):1850-60. PubMed ID: 25211369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
    Perzborn E; Heitmeier S; Laux V
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):554-62. PubMed ID: 25848131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.
    Mackman N; Spronk HMH; Stouffer GA; Ten Cate H
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):726-732. PubMed ID: 29449336
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
    Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
    Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VOYAGER PAD contributes to medical therapy for peripheral artery disease.
    Farber A
    J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822
    [No Abstract]   [Full Text] [Related]  

  • 36. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
    Rivera-Caravaca JM; Camelo-Castillo A; Ramírez-Macías I; Gil-Pérez P; López-García C; Esteve-Pastor MA; Orenes-Piñero E; Tello-Montoliu A; Marín F
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
    Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S
    J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.
    Petersohn S; Pouwels X; Ramaekers B; Ten Cate-Hoek A; Joore M
    Eur J Prev Cardiol; 2020 Sep; 27(13):1354-1365. PubMed ID: 32223323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
    Ambler GK; Nordanstig J; Behrendt CA; Twine CP
    Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837
    [No Abstract]   [Full Text] [Related]  

  • 40. Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
    Sheth MS; Yu B; Chu A; Porter J; Tam DY; Ferreira-Legere LE; Goodman SG; Farkouh ME; Ko DT; Abdel-Qadir H; Udell JA
    J Am Heart Assoc; 2022 Dec; 11(24):e026553. PubMed ID: 36515238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.